Companies Collaborate to Develop More mRNA Vaccines for Other Viruses

March 5, 2021

(WP) It would appear as though COVID-19 isn’t the only virus to be treated with new mRNA and nanoparticle vaccine technologies. In a press release issued yesterday, ConserV Bioscience announced plans to collaborate with eTheRNA to develop new vaccine candidates for other infectious diseases.

ConserV is a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases. eTheRNA is a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its ground-breaking TriMix technology.

This collaboration brings together ConserV's expertise in identifying broadly-protective antigens and eTheRNA's TriMix immunostimulatory mRNA technology and novel lipid nanoparticle ("LNP") encapsulation technologies. Initially, the collaboration will focus on development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV).

To learn more about this partnership start here.

---